Search research articles
Contact Us
Filters
Showing results (101-110 of 113) with videos related to
Page
of 12
Sort By:
Journal of Clinical Psychopharmacology
|
July 17, 2007
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis
Joo Cheol Shim, Byeong Moo Choe, Jung Gee Kim, et al.
Biological Psychiatry
|
January 28, 2004
Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits
Yogesh Dwivedi, Hooriyah S Rizavi, Pradeep K Shukla, et al.
Cephalalgia : an International Journal of Headache
|
February 14, 2020
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
David W Dodick, Peter J Goadsby, Christian Lucas, et al.
The Journal of Clinical Psychiatry
|
April 11, 2009
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia
Deanna L Kelly, Robert W Buchanan, Douglas L Boggs, et al.
Bipolar Disorders
|
November 27, 2008
Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients
William T Regenold, K Calvin Hisley, Pornima Phatak, et al.
Schizophrenia Research
|
December 6, 2011
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial
Douglas L Boggs, Deanna L Kelly, Robert P McMahon, et al.
Journal of Clinical Psychopharmacology
|
January 2, 2013
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study
Kimberly R Warren, Robert W Buchanan, Stephanie Feldman, et al.
Clinical Neuropharmacology
|
August 3, 2005
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia
Robert R Conley, Deanna L Kelly, Matthew W Nelson, et al.
Schizophrenia Research
|
September 18, 2004
The heterogeneity of schizophrenia in disease states
Penny E Mohr, C Michael Cheng, Karl Claxton, et al.
The New England Journal of Medicine
|
July 11, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
Peter J Goadsby, David W Dodick, Massimo Leone, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 113) with videos related to
Sort By:
Page
of 12
Journal of Clinical Psychopharmacology
|
July 17, 2007
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis
Joo Cheol Shim, Byeong Moo Choe, Jung Gee Kim, et al.
Biological Psychiatry
|
January 28, 2004
Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits
Yogesh Dwivedi, Hooriyah S Rizavi, Pradeep K Shukla, et al.
Cephalalgia : an International Journal of Headache
|
February 14, 2020
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
David W Dodick, Peter J Goadsby, Christian Lucas, et al.
The Journal of Clinical Psychiatry
|
April 11, 2009
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia
Deanna L Kelly, Robert W Buchanan, Douglas L Boggs, et al.
Bipolar Disorders
|
November 27, 2008
Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients
William T Regenold, K Calvin Hisley, Pornima Phatak, et al.
Schizophrenia Research
|
December 6, 2011
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial
Douglas L Boggs, Deanna L Kelly, Robert P McMahon, et al.
Journal of Clinical Psychopharmacology
|
January 2, 2013
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study
Kimberly R Warren, Robert W Buchanan, Stephanie Feldman, et al.
Clinical Neuropharmacology
|
August 3, 2005
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia
Robert R Conley, Deanna L Kelly, Matthew W Nelson, et al.
Schizophrenia Research
|
September 18, 2004
The heterogeneity of schizophrenia in disease states
Penny E Mohr, C Michael Cheng, Karl Claxton, et al.
The New England Journal of Medicine
|
July 11, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
Peter J Goadsby, David W Dodick, Massimo Leone, et al.
Page
of 12